Palabras clave
Recaída local de neoplasia
Quimioterapia
Inmunoterapia
Cómo citar
Resumen
La leucemia linfoblástica aguda es un tipo de cáncer común en niños y adultos jóvenes, y su tratamiento implica el uso de quimioterapia y otros medicamentos. Sin embargo, a pesar de las altas tasas de remisión inicial, muchas personas experimentan recaídas y la supervivencia a largo plazo es baja. Este estudio buscó sintetizar los tratamientos utilizados en casos de leucemia linfoblástica aguda recurrente y su aplicación alrededor del mundo. Se realizó una revisión exhaustiva de estudios retrospectivos y prospectivos publicados entre 2012 y 2022 en bases de datos médicas. Los tratamientos más comunes para la leucemia linfoblástica aguda recurrente incluyen combinaciones de quimioterapia, como la terapia con fludarabina, citarabina y mitoxantrona. También se han utilizado esquemas de inducción más intensivos, como el HyperCVAD. Sin embargo, hay poca experiencia con otros medicamentos, como inhibidores del proteosoma y agentes hipometilantes.
Referencias
Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524-2539.
Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):47-60.
Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, et al. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine. 2016;8:173-183.
Messina M, Chiaretti S, Wang J, Fedullo AL, Peragine N, Gianfelici V, et al. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget. 2016;7(12):13886-13901.
Luca DC. Update on Lymphoblastic Leukemia/Lymphoma. Clin Lab Med. 2021;41(3):405-416.
Colunga-Pedraza PR, Colunga-Pedraza JE, Peña-Lozano SP, Gómez-De León A, Ruiz-Delgado GJ, Ribeiro RC. Diagnosis and treatment of acute lymphoblastic leukemia in Latin lat. Hematology. 2022;27(1):971-976.
Paul S, Short NJ. Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. Curr Oncol Rep. 2022;24(4):427-436.
Huang YY, Liu M, Ruth JS, Potenziani S, Hsu S. Precursor-B-cell-ALL leukemia cutis resembling lipomas: an atypical presentation of a rare entity and a review of the literature. Dermatol Online J. 2017;23(3):1-6.
Bhatia S, Prabhu S, Prabhu M, Parampalli Srinivas S, Kudva R, Belurkar S. Leukaemia cutis unveiling underlying pre-B-cell acute lymphoblastic leukaemia. Australas J Dermatol. 2020;61(1):e111-e113.
Daniel SV, Vani DH, Smith AM, Hill QA, Menon KV. Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult. JOP. 2010;11(1):72-74.
Aldoss I, Stein AS. Advances in adult acute lymphoblastic leukemia therapy. Leuk Lymphoma.2018;59(5):1033–1050.
Ribera JM. Advances in acute lymphoblastic leukemia in adults. Curr Opin Oncol. 2011;23(6):692–699.
Pui CH. Precision medicine in acute lymphoblastic leukemia. Front Med. 2020;14(6):689-700.
Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer . 20031;98(7):1337–1354.
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematol. 2010;95(4):589–596.
Oriol A. Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients. Acta Haematol . 2015;133(1):89–90.
Dinner S, Lee D, Liedtke M. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55(8):1715–1724.
Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077–1082.
Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Cenacchi A, et al. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Haematol. 1996;56(5):308–312.
Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabinecontaining therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81(6):513–520.
Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84(12):792–795.
Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25(5–6):579–583.
Yavuz S, Paydas S, Disel U, Sahin B. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther . 2006;13(5):389–393.
Yılmaz Bengoa Ş, Ataseven E, Kızmazoğlu D, Demir Yenigürbüz F, Erdem M, Ören H. FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center. Turk J Haematol. 2017;34(1):46–51.
Alwan AF, Matti BF, Naji AS, Jawad AM. The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients. Indian J Hematol Blood Transfus. 2014;30(4):231–235.
Hassan IB, Kristensen J, Al Qawasmeh K, Alam A. Re-induction chemotherapy using FLAGmitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates. Int J Hematol. 2018;108(4):390–401.
Demichelis-Gómez R, Crespo-Solís E, Pérez- Jacobo LF, Valencia-Rocha UR, Rosas-López A. Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias. Rev Invest Clin. 2015;67(5):287–295.
Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol. 2004;83(11):696–703.
Choi JY, Hong CR, Hong KT, Kang HJ, Kim S, Lee JW, et al. Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea. Cancer Res Treat. 2021;53(4):1184–1194.
Barba P, Sampol A, Calbacho M, González J, Serrano J, Martínez P, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol. 2012;87(6):631–634.
Liedtke M, Dunn T, Dinner S, Coutré SE, Berube C, Gotlib J, et al. Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leuk Res. 2014;38(12):1441–1445.
Faderl S, Thomas DA, O’Brien S, Ravandi F, García-Manero G, Borthakur G, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11(1):54–59.
De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol. 2014;93(12):2011–2018.
Hentosh P, Peffley DM. The cladribine conundrum: deciphering the drug’s mechanism of action. Expert Opin Drug Metab Toxicol. 2010;6(1):75–81.
Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009;78(11):1351–1359.
Lech-Maranda E, Korycka A, Robak T. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem. 2009;9(7):805–812.
Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2007;7(2):113–118.
McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol. 2009;84(4):228–230.
Huguet F, Leguay T, Raffoux E, Rousselot P, Vey N, Pigneux A, et al. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. Leuk Lymphoma. 2015;56(4):847–857.
Rijneveld A, van der Holt B, de Weerdt O, Biemond B, van de Loosdrecht A, van der Wagen L, et al. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Adv. 2022;6(4):1115-1125.
Sanford M, Lyseng-Williamson KA. Nelarabine. Drugs. 2008;68(4):439-447.
Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/ refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020;95(12):1466-1472.
Candoni A, Lazzarotto D, Petruzzellis G. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. Expert Opin Drug Saf. 2021;20(7):751-756.
Ahn J, Yang D, Jung S, Lee J, Kim I, Park S, et al. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. Acta Haematol. 2015;133(1):91-97.
Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, et al. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. Leuk Lymphoma. 2016;57(11):2541-2547.
Narayanan S, Cai C, Assaraf Y, Guo H, Cui Q, Wei L, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.
Dou Q, Zonder J. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 2014;14(6):517-536.
Pordanjani S, Hosseinimehr S. The Role of NFkB Inhibitors in Cell Response to Radiation. Curr Med Chem. 2016;23(34):3951-3963.
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas D, et al. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. PLoS One. 2017;12(12):0188680.
Simioni C, Conti I, Varano G, Brenna C, Costanzi E, Neri LM. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies. Front Oncol. Front Oncol. 2021;11:1-14.
Kyca T, Pavlíková L, Boháčová V, Mišák A, Poturnayová A, Breier A, et al. Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells. Int J Mol Sci. 2021;22(11):1-27.
Horton TM, Whitlock JA, Lu X, O’Brien MM, Borowitz MJ, Devidas M, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol. 2019;186(2):274–285.
Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176(4):629–636.
Colunga-Pedraza JE, González-Llano O, González-Martínez CE, Gómez-Almaguer D, Yáñez-Reyes JM, Jiménez-Antolínez V, et al. Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience. Pediatr Blood Cancer. 2020;67(5):e28241.
Nachmias B, Shaulov A, Gatt ME, Shapira M, Gural A. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Acta Haematol. 2018;140(4):209–214.
Cheung LC, de Kraa R, Oommen J, Chua GA, Singh S, Hughes AM, et al. Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia. Front Oncol. 2021;11:1-13.
Roeten MSF, van Meerloo J, Kwidama ZJ, Ter Huizen G, Segerink WH, Zweegman S, et al. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells. 2021;10(3):1:14.
Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, et al. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Leuk Lymphoma. 2022;63(6):1428–1435.
Jabbour E, Issa JP, García-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112(11):2341–2351.
Schneider P, Castro P, Pinhanços SM, Kerstjens M, van Roon EH, Essing AHW, et al. Decitabine mildly attenuates MLL-rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo-sensitizer. EJHaem. 2020;1(2):527–536.
Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, et al. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020;26(10):2297–2307.
Witkowski MT, Lasry A, Carroll WL, Aifantis I. Immune-Based Therapies in Acute Leukemia. Trends Cancer. 2019;5(10):604–618.
Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2606–2621.
Jabbour E, Pui CH, Kantarjian H. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018;4(10):1413–1420.
Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70-86.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836–847.
Topp MS, Gökbuget N, Zugmaier G, Stein AS, Dombret H, Chen Y, et al. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Cancer. 2021;127(4):554–559.
Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, et al. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Sci. 2020;111(4):1314–1323.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
Kantarjian HM, Stein AS, Bargou RC, Grande C, Larson RA, Stelljes M, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016;122(14):2178-2185.
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Rambaldi A, et al. Long-term followup of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107-114.
Al-Salama ZT. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia. Target Oncol. 2018;13(4):525-532.
Lamb YN. Inotuzumab Ozogamicin: First Global Approval. Drugs. 2017;77(14):1603-1610.
Li X, Zhou M, Qi J, Han Y. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):e227-e247.
Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O’Brien SM, et al. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021;27(10):2742-2754.
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474-2487.
Müller F, Cunningham T, Beers R, Bera TK, Wayne AS, Pastan I. Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins (Basel). 2018;10(5):210-222.
Shah NN, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, et al. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(5):e28112.
Jabbour E, Kantarjian H. A new era in the treatment of acute lymphoblastic leukemia. Blood. 2021;137(12):1563-1564.
Khademi R, Mohammadi Z, Khademi R, Saghazadeh A, Rezaei N. Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies. Nanoscale Adv. 2023;5(3):571-595.
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2024 Médicas UIS